Kyoto University spin-off drug discovery and development company developing KUS small-molecule compounds for difficult-to-treat eye diseases, including central retinal artery occlusion (CRAO), retinitis pigmentosa, age-related macular degeneration, and glaucoma
Kyoto University spin-off drug discovery and development company developing KUS small-molecule compounds for difficult-to-treat eye diseases, including central retinal artery occlusion (CRAO), retinitis pigmentosa, age-related macular degeneration, and glaucoma. Its KUS compounds modulate valosin-containing protein (VCP) and are being investigated for cellular and retinal neuroprotection. KUS121 has received orphan drug designations and U.S. FDA Fast Track designation and is in clinical testing.